Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12791705 | 0.90 | L3MBTL1 (0.34) | HDAC4KDM4EHTTKMT2A | |
| SCHEMBL587429 | 0.90 | HDAC4 (0.33) | HDAC4KDM4E | |
| SCHEMBL16662276 | 0.88 | L3MBTL1 (0.37) | HDAC4KDM4EHTTKMT2A | |
| SCHEMBL19582822 | 0.84 | OPRL1 (0.41) | OPRL1HTT | |
| SCHEMBL31127615 | 0.84 | HRH3 (0.41) | — | |
| SCHEMBL23388445 | 0.78 | — | — | |
| SCHEMBL5206997 | 0.77 | — | — | |
| SCHEMBL2636898 | 0.77 | HTR3A (0.39) | — | |
| SCHEMBL16793351 | 0.75 | — | — | |
| SCHEMBL21853634 | 0.74 | HPGDS (0.42) | HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852223-A | Synthesis method of (2-cyclopropyl-5-pyrimidinyl) boric acid | 浙江江北南海药业有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-121108060-A | Synthesis method of 5-bromo-2-cyclopropyl pyrimidine | 上海瑞合达医药科技有限公司 | 2025-12-12 | — | — | CN | disclosed |
| CN-121108060-A | Synthesis method of 5-bromo-2-cyclopropyl pyrimidine | 上海瑞合达医药科技有限公司 | 2025-12-12 | — | — | CN | disclosed |
| WO-2025242566-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE CNS | Samsara Therapeutics Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4653430-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE CNS | Samsara Therapeutics Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | ASTRAZENECA AB (SE) | 2025-09-02 | — | — | US | disclosed |
| EP-4605388-A1 | <SUP2/>? <SUB2/>?3?2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CXCR1 | Astrazeneca AB (SE) | 2025-08-27 | — | — | EP | disclosed |
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250213560-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF | BNH RESEARCH CO., LTD. (KR) | 2025-07-03 | — | — | US | disclosed |
| CN-120077035-A | As CX32,4, 6-Trisubstituted 1,3, 5-triazines as modulators of CR1 | 阿斯利康(瑞典)有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| US-20080064710-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| CN-101119987-A | Novel compounds | ASTRAZENECA AB GABOS BALINT (SE) | 2008-02-06 | — | — | CN | disclosed |
| EP-1831199-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| CN-1980914-A | Novel hydantoin derivatives for the treatment of obstructive airway diseases. | ASTRAZENECA AB (SE) | 2007-06-13 | — | — | CN | disclosed |
| WO-2006065215-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| EP-1173424-A1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066566-A1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-09 | — | — | WO | disclosed |
| US-4474958-A | 2-Alkyl-5-halopyrimidines | THE DOW CHEMICAL COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
| EP-0097451-A1 | 2-Alkyl-5-pyrimidines | THE DOW CHEMICAL COMPANY (US) | 1984-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | CX3CR1, CCR2, CCR5 | HDAC4 1377/4885OPRL1 113/4885KDM4E 4608/4885 |
| US-20080064710-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | HRH4, HRH1, HRH2 | HDAC4 755/4885OPRL1 470/4885KDM4E 2361/4885 |
| US-20250213560-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF | PNMT, BDNF, NLN | HDAC4 615/4885OPRL1 48/4885KDM4E 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.